FY2024 EPS Estimates for SI-BONE Lifted by Cantor Fitzgerald

SI-BONE, Inc. (NASDAQ:SIBN) – Investment analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for SI-BONE in a research report issued on Wednesday, November 13th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings per share of ($0.69) for the year, up from their prior estimate of ($0.95). The consensus estimate for SI-BONE’s current full-year earnings is ($0.78) per share.

SIBN has been the topic of a number of other research reports. Morgan Stanley lowered their price objective on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Truist Financial lifted their target price on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of SI-BONE in a report on Wednesday, November 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $23.00.

SI-BONE Stock Performance

Shares of SIBN opened at $12.32 on Monday. SI-BONE has a 52-week low of $11.76 and a 52-week high of $21.70. The firm has a market capitalization of $516.70 million, a PE ratio of -13.39 and a beta of 1.22. The firm has a 50-day moving average price of $13.91 and a 200 day moving average price of $14.26. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SIBN. Rhumbline Advisers raised its stake in shares of SI-BONE by 1.5% during the 2nd quarter. Rhumbline Advisers now owns 59,419 shares of the company’s stock worth $768,000 after purchasing an additional 852 shares in the last quarter. Arizona State Retirement System increased its holdings in SI-BONE by 9.0% in the second quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock worth $141,000 after buying an additional 903 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in SI-BONE by 7.5% during the second quarter. The Manufacturers Life Insurance Company now owns 15,880 shares of the company’s stock valued at $205,000 after acquiring an additional 1,105 shares in the last quarter. FMR LLC grew its position in SI-BONE by 103.6% in the third quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after acquiring an additional 1,198 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of SI-BONE by 7.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,494 shares of the company’s stock worth $336,000 after purchasing an additional 1,372 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

Insider Buying and Selling

In other news, insider Anthony J. Recupero sold 3,305 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $13.58, for a total value of $44,881.90. Following the completion of the sale, the insider now directly owns 233,412 shares of the company’s stock, valued at $3,169,734.96. This represents a 1.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders sold 5,060 shares of company stock valued at $72,621. Company insiders own 3.90% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.